FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed is an antibody capable of specifically binding to human erythropoietin. What is also considered is a producing strain of such an antibody.
EFFECT: present invention can find further application in extraction and/or purification of recombinant human erythropoietin by immunoaffinity chromatography.
2 cl, 6 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
1E10 MONOCLONAL MOUSE ANTIBODY 1E10 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI1E10, NEUTRALIZING BACILLUS ANTHRACIS LETHAL TOXIN, AND A STRAIN OF HYBRID CULTURED ABIMAL CELLS -MUS MUSCULUS 1E10 | 2020 |
|
RU2745116C1 |
UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR | 2016 |
|
RU2746486C2 |
ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
BIOSENSOR SYSTEM FOR FAST DETECTION OF DETERMINED COMPONENTS | 2016 |
|
RU2717658C2 |
CHIMERIC PROTEINS BASED ON HUMAN UTROPHIN AND DYSTROPHIN AND USE THEREOF FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | 2021 |
|
RU2767335C1 |
ANAPHYLATOXIN C5A ANTIBODIES TO HUMAN | 2019 |
|
RU2731516C1 |
ANTIBODY AGAINST HUMAN FN14 | 2019 |
|
RU2787044C2 |
Authors
Dates
2020-03-17—Published
2019-01-29—Filed